DNLI

Denali Therapeutics Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$18.89

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %7.4 / %30

Non-compliant assets / Total market cap %33.4 / %30

Non-compliant revenue / Total income %40.9 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).

Website

Analysis (Turkish): DNLI Hissesi Caiz mi, Helal mi? Denali Therapeutics Inc. Katılım Analizi